Clinical trials: Fibrotic Interstitial Lungs Diseases
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Fibrotic Interstitial Lungs Diseases
Physical Activity and Fibrosing Interstitial Lung Disease
Fibrotic interstitial lungs diseases (ILD) are a group of chronic and rare diseases characterized by an altered blood oxygenation in the lung, leading to dyspnea and physical limitation.
- Trial name
- AP-PID (NCT06182748)
- Testing
- Training on eccentric ergocycle, Training on concentric ergocycle
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IPF, Fibrotic Lung Disease
Prognostic Score Comparison in IPF and HP
The goal of this retrospective observational study is to evaluate and compare the prognostic value of GAP, ILD-GAP, and CPI scoring systems in patients diagnosed with interstitial lung diseases (ILDs), specifically Idiopathic…
- Conditions
- IPF, Fibrotic Lung Disease, Hypersensitivity Pneumonitis, Interstitial Lung Disease (ILD)
- Trial name
- NCT07169253
- Testing
- GAP Index, ILD-GAP Index, Composite Physiologic Index (CPI)
- Where
- Turkey (Türkiye)
- Volunteers
- 143 people
- Sponsor
- Saglik Bilimleri Universitesi
Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease
Continuous Versus Demand-Based Oxygen in Patients With Fibrotic Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease
The goal of this randomised clinical trial is to compare the efficacy of exertional oxygen delivery by continous versus demand-based flow systems in patients with fibrotic Interstitial lung disease and chronic obstructive…
- Trial name
- OXYODE (NCT06767904)
- Testing
- Continous Oxygen by Bottles, Demand oxygen by Portable Concentrator
- Volunteers
- 60 people
- Sponsor
- Sissel Kronborg-White
Fibrotic Interstitial Lung Disease
Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease
The goal of this clinical trial is to learn whether artificial intelligence AI-enhanced remote monitoring (AIRM) is feasible, safe and acceptable for adults with fibrotic interstitial lung disease (fILD).
- Trial name
- AIRMILD (NCT07844915)
- Testing
- AIRM v1.0 AI-Enhanced Remote Monitoring
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- King's College London
Idiopathic Pulmonary Fibrosis
Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden
The objective of the current research project is, by using high quality Swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients.
- Trial name
- NCT04019080
- Testing
- Anti-fibrostic drugs
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Karolinska University Hospital
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Fibrotic Interstitial Lung Disease, IPF and PPF
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data…
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Trial name
- RESPOND-ILD (NCT07673237)
- Testing
- Spirometer, Oximeter, Scale
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Pulmonary Fibrosis
An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology
The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary fibrosis will be evaluated.
- Trial name
- I-FILE (NCT04304898)
- Testing
- Home spirometry
- Where
- 2 sites in Netherlands
- Volunteers
- 700 people
- Sponsor
- Erasmus Medical Center